Testing the Combination of an Anti-cancer Drug, Iadademstat, With Other Anti-cancer Drugs (Atezolizumab or Durvalumab) at Improving Outcomes for Small Cell Lung Cancer
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This phase I/II trial tests the safety, side effects, and best dose of iadademstat when given together with atezolizumab or durvalumab, and studies the effect of the combination in treating patients with small cell lung cancer that has spread outside of the lung in which it began or to other parts of the body (extensive stage) who initially received standard of care chemotherapy and immunotherapy. Iadademstat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as atezolizumab or durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Adding iadademstat to either atezolizumab or durvalumab may be able to stabilize cancer for longer than atezolizumab or durvalumab alone in treating patients with extensive stage small cell lung cancer.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Pacjenci z potwierdzonym rakiem płuca typu małych komórek.
- •Pacjenci, którzy przeszli co najmniej 4, ale nie więcej niż 6 cykli standardowego leczenia chemioterapią i immunoterapią, z dobrą lub stabilną odpowiedzią na leczenie.
- •Pacjenci w wieku 18 lat lub starsi.
- •Pacjenci ważący co najmniej 50 kg.
- •Pacjenci mogą połykać leki doustne.
- •Ogólny stan zdrowia pozwalający na codzienne aktywności (według skali ECOG ≤ 2).
✗ Disqualifies
- •Pacjenci poniżej 18 roku życia.
- •Nieprawidłowe wyniki badań krwi (niski poziom białych krwinek, limfocytów, neutrofilów, hemoglobiny, płytek krwi).
- •Nieprawidłowe wyniki badań wątroby lub nerek.
- •Pacjenci z niekontrolowanymi chorobami przewlekłymi, takimi jak niezleczona choroba wątroby B lub C.
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- August 6, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (43)
City of Hope Comprehensive Cancer Center
Duarte, United States
City of Hope at Irvine Lennar
Irvine, United States
UC San Diego Moores Cancer Center
La Jolla, United States
University of California Davis Comprehensive Cancer Center
Sacramento, United States
Smilow Cancer Hospital Care Center at Saint Francis
Hartford, United States
Yale University
New Haven, United States
Yale-New Haven Hospital North Haven Medical Center
North Haven, United States
Smilow Cancer Hospital Care Center at Long Ridge
Stamford, United States
Smilow Cancer Hospital Care Center-Trumbull
Trumbull, United States
MedStar Georgetown University Hospital
Washington D.C., United States
UF Health Cancer Institute - Gainesville
Gainesville, United States
Moffitt Cancer Center
Tampa, United States
Emory University Hospital Midtown
Atlanta, United States
Emory University Hospital/Winship Cancer Institute
Atlanta, United States
Emory Saint Joseph's Hospital
Atlanta, United States
University of Chicago Comprehensive Cancer Center
Chicago, United States
UC Comprehensive Cancer Center at Silver Cross
New Lenox, United States
University of Chicago Medicine-Orland Park
Orland Park, United States
UChicago Medicine Northwest Indiana
Crown Point, United States
University of Kansas Clinical Research Center
Fairway, United States
University of Kansas Cancer Center
Kansas City, United States
University of Kansas Hospital-Indian Creek Campus
Overland Park, United States
University of Kansas Hospital-Westwood Cancer Center
Westwood, United States
University of Kentucky/Markey Cancer Center
Lexington, United States
University of Maryland/Greenebaum Cancer Center
Baltimore, United States
Johns Hopkins University/Sidney Kimmel Cancer Center
Baltimore, United States
Memorial Sloan Kettering Basking Ridge
Basking Ridge, United States
Memorial Sloan Kettering Monmouth
Middletown, United States
Memorial Sloan Kettering Bergen
Montvale, United States
Memorial Sloan Kettering Commack
Commack, United States
Memorial Sloan Kettering Westchester
Harrison, United States
Memorial Sloan Kettering Cancer Center
New York, United States
Memorial Sloan Kettering Nassau
Uniondale, United States
Carolinas Medical Center/Levine Cancer Institute
Charlotte, United States
Atrium Health Cabarrus/LCI-Concord
Concord, United States
Wake Forest University Health Sciences
Winston-Salem, United States
University of Cincinnati Cancer Center-UC Medical Center
Cincinnati, United States
Case Western Reserve University
Cleveland, United States
Ohio State University Comprehensive Cancer Center
Columbus, United States
University of Cincinnati Cancer Center-West Chester
West Chester, United States
UPMC Hillman Cancer Center
Pittsburgh, United States
University of Virginia Cancer Center
Charlottesville, United States
VCU Massey Comprehensive Cancer Center
Richmond, United States
Trial contact
Site Public Contact
Matthew Lee
PRINCIPAL_INVESTIGATOR
Site Public Contact
Site Public Contact
Lyudmila A. Bazhenova
PRINCIPAL_INVESTIGATOR
Site Public Contact
Surbhi Singhal
PRINCIPAL_INVESTIGATOR
Site Public Contact
Anne C. Chiang
PRINCIPAL_INVESTIGATOR
Site Public Contact
Stephen V. Liu
PRINCIPAL_INVESTIGATOR
Site Public Contact
Aline F. Fares
PRINCIPAL_INVESTIGATOR
Site Public Contact
Ticiana A. Leal
PRINCIPAL_INVESTIGATOR
Site Public Contact
Site Public Contact
Site Public Contact
Noura Choudhury
PRINCIPAL_INVESTIGATOR
Site Public Contact
Site Public Contact
Chao H. Huang
PRINCIPAL_INVESTIGATOR
Site Public Contact
Zhonglin Hao
PRINCIPAL_INVESTIGATOR
Site Public Contact
Samuel Rosner
PRINCIPAL_INVESTIGATOR
Site Public Contact
Christine L. Hann
PRINCIPAL_INVESTIGATOR
Site Public Contact
Charles M. Rudin
PRINCIPAL_INVESTIGATOR
Site Public Contact
Christopher R. Pallas
PRINCIPAL_INVESTIGATOR
Site Public Contact
Jimmy Ruiz
PRINCIPAL_INVESTIGATOR
Site Public Contact
Jennifer Leddon
PRINCIPAL_INVESTIGATOR
Site Public Contact
Afshin Dowlati
PRINCIPAL_INVESTIGATOR
Site Public Contact
Asrar AlAhmadi
PRINCIPAL_INVESTIGATOR
Site Public Contact
Liza C. Villaruz
PRINCIPAL_INVESTIGATOR
Site Public Contact
Ryan D. Gentzler
PRINCIPAL_INVESTIGATOR
Site Public Contact
Jonathan D. Berkman
PRINCIPAL_INVESTIGATOR
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/31/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.